Clinical Trial

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Vaxcyte Appoints John Furey to Board of Directors

SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines…

2 years ago

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 DeficiencyBOSTON, July 02, 2024…

2 years ago

Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO

Dahan brings over two decades of experience in the life sciences industry transforming companies from early pre-clinical stage development to…

2 years ago

180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the…

2 years ago

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than…

2 years ago

Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study

DALLAS, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

2 years ago

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

2 years ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…

2 years ago

Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results

Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), is pleased to…

2 years ago